The US stock-listed Ethereum treasury company Propanc Biopharma announced the acquisition of the undervalued DAT entity.

2025-11-04 12:19:49

Abstract generation in progress

According to a report by GLOBE NEWSWIRE on November 4, Deep Tide TechFlow announced that Nasdaq-listed biopharmaceutical company Propanc Biopharma (PPCB) has initiated a strategic acquisition plan, targeting the acquisition of the digital asset treasury (DAT) company with a market capitalization below its net asset value.

The company's management believes that the acquisition of undervalued DAT entities will help strengthen the balance sheet, achieve asset diversification, and create long-term shareholder value. These DAT companies often hold substantial reserves of mainstream digital assets such as Bitcoin and Ethereum on their balance sheets.

CEO James Nathanielsz stated that this is a strategic diversification initiative aimed at unlocking value for shareholders while continuing to advance the innovative oncology pipeline. The company's board and executive team are evaluating potential acquisition targets.

Previously, Propanc Biopharma announced plans for an acquisition of 100 million US dollars in Ethereum.

ETH-13.64%

BTC-7.19%

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.